Junshi BIO (01877) rose more than 3% again, with the stock up 2.83% to HK$28.32 at the time of writing. The turnover reached HK$108 million. The global oncology conference, the American Association for Cancer Research (AACR) 2026 Annual Meeting, is scheduled to take place from April 17 to 22, 2026, at the San Diego Convention Center in the United States. Pacific Securities noted that Junshi Bio's JS207 (PD-1/VEGF) will disclose clinical data for first-line colorectal cancer (in combination with chemotherapy) and first-line hepatocellular carcinoma (in combination with CTLA-4 monoclonal antibody) at the 2026 AACR meeting, with potential entry into key registration clinical trials within the year. JS212 (EGFR/HER3 ADC) will present early-stage data at AACR, with plans to initiate pivotal registration trials by the end of the year.